Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Palisade Bio Gelecekteki Büyüme
Future kriter kontrolleri 0/6
Palisade Bio's earnings are forecast to decline at 18.4% per annum. EPS is expected to decline by 0.5% per annum.
Anahtar bilgiler
-18.4%
Kazanç büyüme oranı
-0.5%
EPS büyüme oranı
Biotechs kazanç büyümesi | 28.6% |
Gelir büyüme oranı | n/a |
Gelecekteki özkaynak getirisi | n/a |
Analist kapsamı | Low |
Son güncelleme | 09 Sep 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Palisade Bio announces CEO transition
Oct 11Palisade Bio streamlines operations, including cutting 20% of employees
Sep 15Palisade Bio GAAP EPS of -$0.12
Aug 15Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function
Jul 27Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy
Jun 29Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely
Mar 28Palisade Bio: Guarding Intestinal Integrity
Nov 07Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | N/A | -25 | N/A | N/A | 2 |
12/31/2025 | N/A | -21 | N/A | N/A | 2 |
12/31/2024 | N/A | -16 | N/A | N/A | 2 |
6/30/2024 | N/A | -14 | -12 | -12 | N/A |
3/31/2024 | N/A | -14 | -11 | -11 | N/A |
12/31/2023 | 0 | -12 | -11 | -11 | N/A |
9/30/2023 | 0 | -13 | -12 | -12 | N/A |
6/30/2023 | 0 | -14 | -12 | -12 | N/A |
3/31/2023 | 0 | -13 | -13 | -13 | N/A |
12/31/2022 | N/A | -15 | -13 | -13 | N/A |
9/30/2022 | N/A | -9 | -13 | -13 | N/A |
6/30/2022 | N/A | 0 | -13 | -13 | N/A |
3/31/2022 | N/A | -27 | -17 | -17 | N/A |
12/31/2021 | N/A | -27 | -15 | -15 | N/A |
9/30/2021 | N/A | -32 | -13 | -13 | N/A |
6/30/2021 | N/A | -39 | -11 | -11 | N/A |
3/31/2021 | N/A | -12 | -5 | -5 | N/A |
12/31/2020 | N/A | -10 | -5 | -5 | N/A |
9/30/2020 | N/A | -9 | -5 | -5 | N/A |
12/31/2019 | N/A | -10 | -7 | -7 | N/A |
12/31/2018 | 1 | -4 | -2 | -2 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: PALI is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: PALI is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: PALI is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: Insufficient data to determine if PALI's revenue is forecast to grow faster than the US market.
Yüksek Büyüme Geliri: PALI is forecast to have no revenue next year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if PALI's Return on Equity is forecast to be high in 3 years time